A carregar...
Current status of intralesional agents in treatment of malignant melanoma
Prognosis of metastatic melanoma has undergone substantial improvement with the discovery of checkpoint inhibitors. Immunotherapies and targeted therapies have improved the median overall survival (OS) of metastatic melanoma from 6 months to more than 3 years. However, still about half of the patien...
Na minha lista:
| Publicado no: | Ann Transl Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8267328/ https://ncbi.nlm.nih.gov/pubmed/34277838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-21-491 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|